TITLE

Application of Scaling Factors in Simultaneous Modeling of Microarray Data from Diverse Chips

AUTHOR(S)
Zhenling Yao; Baiteng Zhao; Eric Hoffman; Svetlana Ghimbovschi; William Jusko
PUB. DATE
April 2007
SOURCE
Pharmaceutical Research;Apr2007, Vol. 24 Issue 4, p643
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
AbstractPurpose??Microarrays have been utilized in many biological, physiological and pharmacological studies as a high-throughput genomic technique. Several generations of Affymetrix GeneChip?microarrays are widely used in gene expression studies. However, differences in intensities of signals for different probe sets that represent the same gene on various types of Affymetrix chips make comparison of datasets complicated.Materials and Methods??A power coefficient scaling factor was applied in the pharmacokinetic/pharmacodynamic (PK/PD) modeling to account for differences in probe set sensitivities (i.e., signal intensities). Microarray data from muscle and liver following methylprednisolone 50?mg/kg i.v. bolus and 0.3?mg/kg/h infusion regimens were taken as an exemplar.Results??The scaling factor applied to the pharmacodynamic output function was used to solve the problem of intensity differences between probe sets. This approach yielded consistent pharmacodynamic parameters for the applied models.Conclusions??Modeling of pharmacodynamic/pharmacogenomic (PD/PG) data from diverse chips should be performed with caution due to differential probe set intensities. In such circumstances, a power scaling factor can be applied in the modeling.
ACCESSION #
24397255

 

Related Articles

  • Steady-State Pharmacokinetics of Roflumilast and Roflumilast N-Oxide in Patients with Mild and Moderate Liver Cirrhosis. Hermann, Robert; Nassr, Nassr; Lahu, Gezim; Péterfai, Éva; Knoerzer, Dietrich; Herzog, Roif; Zech, Karl; de Mey, Christian // Clinical Pharmacokinetics;2007, Vol. 46 Issue 5, p400 

    Background: Roflumilast and its primary N-oxide metabolite are targeted phosphodiesterase 4 (PDE4) inhibitors with similar in vivo potency. Roflumilast is being developed for the treatment of inflammatory airway diseases such as chronic obstructive pulmonary disease and asthma. Objective: To...

  • Influence of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Landiolol Hydrochloride, an Ultra-Short-Acting β1-Blocker. Takahata, Takenori; Yasui-Furukori, Norio; Sakamoto, Juichi; Suto, Koji; Suto, Toshiyuki; Tateishi, Tomonori; Munakata, Akihiro // Drugs in R&D;2005, Vol. 6 Issue 6, p385 

    Objective: To investigate the effects of mild to moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, a new ultra-short-acting β1-adrenergic antagonist. Methods: Six patients with hepatic impairment and six healthy volunteers were enrolled in...

  • A Microscale In Vitro Physiological Model of the Liver: Predictive Screens for Drug Metabolism and Enzyme Induction. Sivaraman, A.; Leach, J. K.; Townsend, S.; Iida, T.; Hogan, B. J.; Stolz, D. B.; Fry, R.; Samson, L. D.; Tannenbaum, S. R.; Griffith, L. G. // Current Drug Metabolism;Dec2005, Vol. 6 Issue 6, p569 

    In vitro models of the liver using isolated primary hepatocytes have been used as screens for measuring the metabolism, toxicity and efficacy of xenobiotics, for studying hepatocyte proliferation, and as bioartificial liver support systems. Yet, primary isolated hepatocytes rapidly lose liver...

  • Modification of pharmacokinetics of norfloxacin following oral administration of curcumin in rabbits. Pavithra, B. H.; Prakash, N.; Jayakumar, K. // Journal of Veterinary Science;2009, Vol. 10 Issue 4, p293 

    investigation was carried out in adult New Zealand white rabbits to study the influence of curcumin pre-treatment on pharmacokinetic disposition of norfioxacin following single oral administration. Sixteen rabbits were divided into two groups of eight each consisting of either sex. Animals in...

  • A Perspective on Reconciling Mass Balance in Forced Degradation Studies. Lukulay, Patrick; Hokanson, Gerard // Pharmaceutical Technology;Oct2005, Vol. 29 Issue 10, p106 

    Focuses on two scenarios that demonstrate the need to use the percent of parent drug loss rather than the percent of degradation products formed when reconciling mass balance calculations. Quality control check on analytical methods to show that all degradation products are adequately detected...

  • Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin. Takahashi, H.; Echizen, H. // Pharmacogenomics Journal;2003, Vol. 3 Issue 4, p202 

    Summarizes clinical data on the relation between the CYP2C9 polymorphisms and the daily dose requirement of warfarin as well as the susceptibility to bleeding complications, and the impact of CYP2C9 polymorphisms on the pharmacokinetics of (S)-warfarin in different populations. Introduction to...

  • Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. Li-mei Han; Jie Guo; Li-jun Zhang; Qing-song Wang; Xiao-ling Fang // Acta Pharmacologica Sinica;Jun2006, Vol. 27 Issue 6, p747 

    Aim: To investigate the preparation, in vitro release, in vivo pharmacokinetics and tissue distribution of a novel polymeric micellar formulation of paclitaxel (PTX) with Pluronic P123. Methods: The polymeric micelles of paclitaxel with Pluronic P123 were prepared by a solid dispersion method....

  • Pharmacokinetics. Vohr, Hans-Werner // Encyclopedic Reference of Immunotoxicology;2005, p495 

    A definition of the term "pharmacokinetics" is presented. It refers to the study of bodily absorption, distribution, metabolism, and excretion of drugs.

  • Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs. Guti‚rrez, Lilia; Velasco, Zazil-Ha; V zquez, Carlos; Vargas, Dinorah; Sumano, H‚ctor // Acta Veterinaria Scandinavica;2012, Vol. 54 Issue 1, p35 

    Based on its PK/PD ratios, doxycycline hyclate (DOX-h), a time-dependant antibacterial, is ideally expected to achieve both sustained plasma drug concentrations at or slightly above the MIC level for as long as possible between dosing intervals. Pursuing this end, a poloxamer-based matrix was...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics